The Scientist

» drug development, disease/medicine and ecology

Most Recent

image: Psychedelic Neuroimaging

Psychedelic Neuroimaging

By | April 13, 2016

“Ego dissolution,” and other things that happen to the human brain on LSD

0 Comments

image: Cancer Tissue Repository Launched

Cancer Tissue Repository Launched

By | April 11, 2016

The Dana-Farber Cancer Institute will store tissue samples from patients with leukemia and lymphoma from which scientists can make patient-derived mouse models.

0 Comments

image: Zooming In on an Antidepressant Target

Zooming In on an Antidepressant Target

By | April 6, 2016

Structural studies reveal how SSRI drugs bind to the human serotonin transporter.

0 Comments

image: Book Excerpt from <em>The Serengeti Rules</em>

Book Excerpt from The Serengeti Rules

By | April 1, 2016

In the introduction to the book, author Sean B. Carroll draws the parallels between ecological and physiological maladies.

0 Comments

image: Contributors

Contributors

By | April 1, 2016

Meet some of the people featured in the April 2016 issue of The Scientist.

0 Comments

image: Parallel Plagues

Parallel Plagues

By | April 1, 2016

Like cancer, ecological scourges result from the breakdown of regulatory processes, and may be treated with similar logic.

0 Comments

image: Pulling It All Together

Pulling It All Together

By | April 1, 2016

Systems-biology approaches offer new strategies for finding hard-to-identify drug targets for cancer.

0 Comments

image: Shooting for the Moon

Shooting for the Moon

By | April 1, 2016

Defeating cancer is many times more difficult than planting a flag on our lunar satellite.

4 Comments

image: Another Drug Price Hike

Another Drug Price Hike

By | March 28, 2016

Valeant Pharmaceuticals is criticized for jacking up the price of a drug used in assisted suicide.

0 Comments

image: CDC Offers Advice to Limit Opioid Scripts

CDC Offers Advice to Limit Opioid Scripts

By | March 17, 2016

Aimed at primary care providers, the recommendations encourage non-narcotic alternatives or short-term opioid prescriptions and patient monitoring.

0 Comments

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. Does Productivity Diminish Research Quality?
  3. How Plants Evolved Different Ways to Make Caffeine
  4. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

RayBiotech